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1he Ultimate Solution to the
roblem of Aspirin Resistance
n their State-of-the-Art paper, Gasparyan et al. (1) provide an
xcellent review of the potential factors responsible for aspirin
esistance. As they point out, a major problem is the lack of an
ccurate, reproducible, and practical quantitative test for measuring
latelet activation. All commercially available tests use the mea-
urement of the transmission of light through a suspension of
latelets or the passage of cells through a narrow aperture. Both of
hese techniques are limited in that they detect macroaggregates
ut not microaggregates of platelets. This limitation is easily
emonstrated by performing a dose-response test by adding
inearly increasing doses of a glycoprotein IIb/IIIa inhibitor such as
bciximab, eptifibatide, or tirofiban to the sample before measuring
he percent inhibition produced by the addition. When this is done
ith any of the commercially available tests and the dose is plotted
gainst the percent inhibition, the response in not linear, but
attens out at approximately 80% inhibition, which is close to the
egree of inhibition that is likely to be clinically desirable. This
roblem can be overcome if, instead of using the commercial tests,
ne uses an automatic cell counter to count individual platelets
efore and after the addition of the agonist. The percent inhibition
s the difference between the before and after counts divided by the
efore count. When a dose-response test with a glycoprotein
Ib/IIIa inhibitor is performed by using this technique, the
esponse is linear throughout the entire range of inhibition. An
deal test for platelet activation would eliminate the need for the
se of an agonist. Such a test would reflect in vivo activation at the
ime the sample was drawn. To avoid use of an agonist, it would
eed to be extremely sensitive. To allow for establishment of its
pecificity, it would need to be quantitative. When platelets
ecome activated, one of the first effects is the release of platelet
icroparticles that can be identified by flow cytometry. These
icroparticles have all of the surface markers of platelets that can
e detected with fluorescent-labeled antibodies. Because each
ctivated platelet releases large numbers of microparticles, each
ith multiple markers, a modified flow cytometer could be developed
pecifically to detect these markers on microparticles and, thus, be a
ery sensitive measure of platelet activation. Such a machine would
ave great utility as a tool for adjusting the doses of antiplatelet
herapy, detecting resistance to antiplatelet agents such as aspirin
nd clopidogrel, and in detecting early acute cardiac events.
Bruce A. Kottke, MD
Internal Medicine
lark and Daughtrey LLP
30 Pablo Street
akeland, Florida 33803
-mail: Integretec@aol.comdoi:10.1016/j.jacc.2008.06.041
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nteric Coating Is a Possible
ause of Aspirin Resistance
he observation that aspirin does not inhibit platelet function
s expected in some patients has been referred to as “aspirin
esistance.” The reported increased incidence of cardiovascular
vents in patients exhibiting aspirin resistance is indeed con-
erning (1,2) and highlights the importance of eliminating
odifiable etiologies. In a recent issue of the Journal, Gasparyan
t al. (3) discussed several of these causes, including poor
ompliance, nonsteroidal anti-inflammatory agents, and proton
ump inhibitors. It is also important to take note of recent
eports of incomplete suppression of platelet aggregation with
nteric-coated aspirin (4,5). In a randomized, open-label, cross-
ver study of healthy volunteers, incomplete thromboxane (TX)
2 inhibition was found to occur in 8% of the aspirin group and
4.3% of the enteric-coated aspirin group (p  0.0004) (4). In
nother study of 131 stable cardiovascular patients treated with
nteric-coated aspirin (75 mg/d), 44% of patients failed to
ttain optimal inhibition of serum TX, indicating suboptimal
nhibition of platelet COX-1 activity, and those with an
ncomplete aspirin response were more likely to demonstrate
latelet aggregation to arachidonic acid (21% vs. 3%; p  0.004)
5). These data are of increasing importance when considering
spirin resistance because many patients now receive low-dose
nteric-coated aspirin preparations for primary and secondary
revention of cardiovascular events.
John R. Kapoor, MD, PhD
Division of Cardiology
tanford University
00 Pasteur Drive
tanford, California 94305
-mail: jkapoor@stanford.edu
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eply
e thank the 2 authors for their interest in our review (1), in
hich a number of issues were raised regarding definition, possible
auses, detection, and treatment of “aspirin resistance.” The
mergence of the latter requires, first of all, the selection of specific,
eproducible, simple, and standardized platelet function tests that
ould distinguish patients responding to COX-1–related aspirin
ffects from those patients in whom the administration of aspirin
ails to inhibit production of thromboxane A2 through COX-1–
elated pathway(s). The latter is viewed by us as a true incident of
laboratory aspirin resistance.”
The most specific test for the assessment of aspirin effects is
ight transmission platelet aggregometry with low concentrations
f arachidonic acid and adenosine diphosphate. This method is
idely used in almost all large prospective studies of aspirin
esistance and is closely associated with occurrence of cardiovas-
ular events. Its use allows the clinician to assess platelet function
y forming macroaggregates of platelets and is characterized by
ore serious limitations. First and foremost, platelet aggregometry
equires the use of different agonists at different concentrations and
heir (ex vivo) addition to platelet-rich plasma. A frequently used
gonist, arachidonic acid, has been criticized for its possible lytic
ffects on platelets, resulting in an increase of the light transmis-
ion through platelets suspension without an increase in the level
f macroaggregates (2). Another frequently used agonist, adeno-
ine diphosphate at low concentrations, can partly activate the
rachidonic acid cascade, but its main effect is not specific for the
OX-1 pathway. Also, the adjustment of platelet count in
latelet-rich plasma by adding autologous platelet-poor plasma,
hich is mandatory for platelet aggregometry, can itself suppress
latelet function (3). Thus, laboratory preparation and the use of
gonists for platelet aggregometry can cause unpredictable results,
ar from reflecting true platelet function per se in cardiovascular
isease patients taking aspirin.
Thus, we would agree with the comments that we should avoid
he use of agonists for the “ideal test” of aspirin resistance, but this
uggestion probably requires the revision of the current definition
f “laboratory aspirin resistance.” From the physiological point of
iew, platelet aggregometry in platelet-rich plasma is also an in
itro time-consuming test that neglects interactions of platelets
ith leucocytes and erythrocytes at the time of blood sampling.
his problem is partly overcome with the use of whole blood
ggregometry and semiautomated point-of-care platelet function
ssays that use whole blood (e.g., the PFA-100 test, Siemens
ealth Diagnostics, Newark, Delaware), which again exhibits a
umber of other limitations.
It was thought that the use of light transmission aggregometry
n combination with other platelet function tests could avoid the
imitations of different tests and provide a comprehensive assess- dent of platelet function. However, this alternative approach raises
nother important question as to how interpret different, and
ometimes polarized, results of different tests. One of the latest
tudies (4) assessing the prevalence of aspirin resistance with
everal major platelet function tests (e.g., light transmission aggre-
ometry, whole blood aggregometry, PFA-100, VerifyNow-
spirin [Accumetrics, San Diego, California], and urinary 11-
ehydrothromboxane B2) yielded a prevalence ranging from 6.7%
by VerifyNow-Aspirin) to 59.5% (by PFA-100). These results
gain confirm the lack of correlation between laboratory tests of
spirin resistance.
We would agree with the comments that flow cytometry is an in
ivo quantitative test for the detection of activated platelets and
elease of microparticles with the surface markers specific for
hromboxane A2 pathway at an early stage of platelet activation,
nd that it may be viewed as an important tool for future studies on
rue prevalence of “laboratory aspirin resistance.” Nonetheless, the
xpense of flow cytometry and the need to assay samples in
ighly-specialized laboratory centers would make it difficult to
mploy flow cytometry in large-scale prospective studies.
Finally, we agree with Kapoor on the suggestion that there is
ncomplete suppression of platelet aggregation with enteric-coated
spirin. Nonetheless, we should not lose sight of the fact that one
ommon explanation for aspirin resistance, whether defined as
aboratory resistance or clinical resistance (i.e., increased throm-
otic events), is noncompliance (5).
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Ib or Not IIb
hite et al. (1) present an interesting case for the ability to switch
o bivalirudin therapy from heparin (unfractionated heparin or
noxaparin) in non–ST-segment elevation acute coronary syn-
rome. The baseline characteristics of the 2 groups (consistent vs.
